Bio Path Holdings Stock Current Valuation
| BPTH Stock | USD 0.80 0.02 2.44% |
Valuation analysis of Bio Path Holdings helps investors to measure Bio Path's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -0.23. The current Enterprise Value Multiple is estimated to decrease to -0.23. Fundamental drivers impacting Bio Path's valuation include:
Price Book 2.335 | Enterprise Value 3 M | Enterprise Value Ebitda 0.0252 |
Undervalued
Today
Please note that Bio Path's price fluctuation is very risky at this time. Calculation of the real value of Bio Path Holdings is based on 3 months time horizon. Increasing Bio Path's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bio Path is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio Stock. However, Bio Path's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 3.59 | Target 12.0 | Hype 0.8 | Naive 0.9 |
The intrinsic value of Bio Path's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Bio Path's stock price.
Estimating the potential upside or downside of Bio Path Holdings helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Path more accurately as focusing exclusively on Bio Path's fundamentals will not take into account other important factors: Bio Path Holdings Company Current Valuation Analysis
Bio Path's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bio Path Current Valuation | 3 M |
Most of Bio Path's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Path Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Path is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Current Valuation. Since Bio Path's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Path's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Path's interrelated accounts and indicators.
Click cells to compare fundamentals
Bio Current Valuation Historical Pattern
Today, most investors in Bio Path Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Path's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Path current valuation as a starting point in their analysis.
Bio Path Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bio Path Holdings has a Current Valuation of 3 M. This is 99.98% lower than that of the Biotechnology sector and 99.94% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Bio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Path's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics of similar companies.Bio Path is currently under evaluation in current valuation category among its peers.
Bio Fundamentals
| Return On Equity | -3.66 | ||||
| Return On Asset | -1.4 | ||||
| Current Valuation | 3 M | ||||
| Shares Outstanding | 4.31 M | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 77.76 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) | ||||
| Cash And Equivalents | 17.02 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.57 X | ||||
| Book Value Per Share | 0.71 X | ||||
| Cash Flow From Operations | (11.54 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (8.34) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 3.53 M | ||||
| Total Asset | 3.22 M | ||||
| Retained Earnings | (107.61 M) | ||||
| Working Capital | 1.14 M | ||||
| Current Asset | 9.59 M | ||||
| Current Liabilities | 937 K | ||||
| Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Bio Path Piotroski F Score and Bio Path Altman Z Score analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.